Trimel Pharmaceuticals Corporation

Trimel Pharmaceuticals Corporation

September 09, 2013 08:15 ET

Trimel Pharmaceuticals Corporation Announces Appointment of New Director

TORONTO, ONTARIO--(Marketwired - Sept. 9, 2013) - Trimel Pharmaceuticals Corporation (TSX:TRL) is pleased to announce the appointment of Mr. Ian Ihnatowycz to its Board of Directors.

Mr. Ihnatowycz currently serves as the President and Chief Executive Officer of First Generation Capital Inc., a private investment holding company. Mr. Ihnatowycz previously served as President and Chief Executive Officer of Acuity Investment Management Inc. and Acuity Funds Ltd. from 1990 until its sale in 2011. Mr. Ihnatowycz has served on the board of directors of a number of public and private companies and a variety of professional and not-for-profit organizations, including the Royal Conservatory. Additionally, Mr. Ihnatowycz is a member of the Ivey Advisory Board and the Ian. O. Ihnatowycz Institute for Leadership Advisory Board, both at the Ivey Business School.

"We are very excited to welcome Mr. Ihnatowycz to the Board," said Bruce Brydon, Chairman of the Board. "With his considerable capital markets expertise and experience, we are confident he will serve as a valuable resource for the Board and help us grow our business at this exciting stage of development. Each of the Board members looks forward to drawing on Mr. Ihnatowycz's considerable knowledge as we move forward."

About Trimel

Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. A New Drug Application for CompleoTRT™, a product utilizing Trimel's licensed bioadhesive intranasal gel technology, has been filed with the United States Food and Drug Administration for regulatory approval in the United States. For more information, please visit

Contact Information